Wiley has announced the 2026 release of Mass Spectra of Designer Drugs, GC-MS spectral database used by forensic laboratories worldwide for rapid identification of illicit substances.
The company stated that the landscape of novel psychoactive substances (NPS) continues to evolve, with increasing numbers of synthetic cannabinoids, metabolites, fentanyl analogs, pharmaceutical drugs and metabolites, derivatives, and other emerging compounds, requiring laboratories to rely on continuously updated reference data.
The latest release includes updates intended to support forensic science, toxicology, and drug surveillance workflows.
● Addition of more than 700 new mass spectra.
● Addition of more than 400 unique compounds spanning key NPS categories including fentanyl variants, xylazine, synthetic opioids such as nitazene opioids, and cannabinoids.
● The database now represents 37,075 total mass spectra and 27,900 unique chemical entities.
The 2026 release strengthens Wiley’s position as a source of spectral intelligence and provides laboratories with data to support the identification of emerging designer drugs, while also supporting forensic and public health work as new substances appear.
The Mass Spectra of Designer Drugs database was developed for forensic and toxicology laboratory environments. According to Wiley, the database is compatible with most major mass spectrometry systems and is also available through a KnowItAll database subscription. When used with Wiley’s KnowItAll software platform, the database provides access to forensic tools, including drug classification models and Wiley’s patented MS Adaptive Search capability.
These tools are intended to assist analysts in identifying and interpreting both known and emerging compounds and support the detection of novel or unusual substances with greater speed and analytical clarity. The company states that these capabilities reinforce the database’s role as a resource for laboratories engaged in drug detection work.
Click here to read the original press release.
